Hepatology Resource Center New litigation forces states to stop restricting HCV treatments July 07, 2016 By Mark L. Fuerst States had restricted Medicaid recipients’ access to drugs, but new court rulings are changing that practice. Primary care treats chronic HCV just as well as specialists June 09, 2016 By Mark L. Fuerst PCPs can “play a decisive role in eradicating” hepatitis C virus in the U.S., says lead author of new study. DAAs safer, more tolerable than interferon for HCV infections June 09, 2016 By Mark L. Fuerst Researchers find that direct-acting antivirals are better tolerated in patients with hepatitis C virus infections vs. interferon-based therapy. Elimination of hepatitis B and C now feasible May 02, 2016 By Mark L. Fuerst A new report finds that hepatitis B and C can be eliminated as a public health problem. Simeprevir, sofosbuvir combo treats HCV patients with cirrhosis April 04, 2016 By Mark L. Fuerst The protease and polymerase inhibitor proved effective and well tolerated in patients with hepatitis C virus and cirrhosis, according to a new study. Perinatal HCV transmission needs national conversation April 04, 2016 By Mark L. Fuerst A new study highlights the need for hepatitis C virus screening of pregnant women to identify HCV-infected children and direct them to proper care. A significant number of babies born to women who are infected with the hepatitis C virus (HCV) remain untested for perinatal infections, according to a new study. Some HCV patients still difficult to treat March 11, 2016 By Mark L. Fuerst Direct-acting antiviral (DAA) agents appear to have a less robust effect in “difficult-to-treat” patients, according to new research. Real-world factors aid HCV patient treatment decisions March 11, 2016 By Mark L. Fuerst A new study explores what lifestyle hepatitis C virus (HCV) patients consider when directing their course of treatement. HCV infection raises risk of developing Parkinson’s February 12, 2016 By Mark L. Fuerst A new study indicates that infection with the hepatitis C virus (HCV) significantly increases the risk of developing Parkinson’s Disease. Antiviral combination eradicates HCV in advanced liver disease February 11, 2016 By Mark L. Fuerst The use of sofosbuvir and velpatasvir successfully treated hepatitis C virus infection in 90% of advanced liver disease patients, a new study notes.